Literature DB >> 29165283

Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues.

Carey J Myers1, Bo Lu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29165283      PMCID： PMC5726785          DOI： 10.1016/j.ijrobp.2017.06.2452

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  75 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation.

Authors:  J H Hong; C S Chiang; C Y Tsao; P Y Lin; W H McBride; C J Wu
Journal:  Int J Radiat Biol       Date:  1999-11       Impact factor: 2.694

Review 3.  Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.

Authors:  Søren M Bentzen
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

Review 4.  Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

Authors:  Teele Kuusk; Laurence Albiges; Bernard Escudier; Nikolaos Grivas; John Haanen; Thomas Powles; Axel Bex
Journal:  Angiogenesis       Date:  2017-04-11       Impact factor: 9.596

Review 5.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

6.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Takafumi Ikeda; Manabu Minami; Atsushi Kawaguchi; Toshinori Murayama; Masashi Kanai; Yukiko Mori; Shigemi Matsumoto; Shunsuke Chikuma; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Akihiko Ueda; Yuko Hosoe; Satoshi Morita; Masayuki Yokode; Akira Shimizu; Tasuku Honjo; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 7.  Cardiac complications of thoracic irradiation.

Authors:  Catherine Jaworski; Justin A Mariani; Greg Wheeler; David M Kaye
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

8.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

Review 9.  Radiation-induced heart disease: pathologic abnormalities and putative mechanisms.

Authors:  Neil K Taunk; Bruce G Haffty; John B Kostis; Sharad Goyal
Journal:  Front Oncol       Date:  2015-02-18       Impact factor: 6.244

10.  Glycyrrhetinic acid alleviates radiation-induced lung injury in mice.

Authors:  Jinmei Chen; Weijian Zhang; Lurong Zhang; Jiemin Zhang; Xiuying Chen; Meichun Yang; Ting Chen; Jinsheng Hong
Journal:  J Radiat Res       Date:  2016-09-26       Impact factor: 2.724
View more
  10 in total

Review 1.  Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.

Authors:  Jianqiong Yin; Yuanjun Wu; Xue Yang; Lu Gan; Jianxin Xue
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

2.  Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

Authors:  Paul Lesueur; Alexandre Escande; Juliette Thariat; Enora Vauléon; Isabelle Monnet; Alexis Cortot; Delphine Lerouge; Serge Danhier; Pascal Dô; Catherine Dubos-Arvis; Christos Chouaïd; Radj Gervais
Journal:  Cancer Med       Date:  2018-10-11       Impact factor: 4.452

3.  Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on Injury.

Authors:  Rachel A Schlaak; Anne Frei; Brian L Fish; Leanne Harmann; Tracy Gasperetti; Jamie L Pipke; Yunguang Sun; Hallgeir Rui; Michael J Flister; Benjamin N Gantner; Carmen Bergom
Journal:  Cancers (Basel)       Date:  2020-04-16       Impact factor: 6.639

Review 4.  A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy.

Authors:  Shuyan Li; Xiao Chu; Luxi Ye; Jianjiao Ni; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2020-10

5.  PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury.

Authors:  Yuling Sheng; Kun Chen; Wei Jiang; Zhiyuan Wu; Wenjue Zhang; Hao Jing; Luhua Wang; Chunfeng Qu; Hua Ren
Journal:  Transl Lung Cancer Res       Date:  2021-02

6.  Gut Microbiota-Derived l-Histidine/Imidazole Propionate Axis Fights against the Radiation-Induced Cardiopulmonary Injury.

Authors:  Zhiyuan Chen; Bin Wang; Jiali Dong; Yuan Li; Shuqin Zhang; Xiaozhou Zeng; Huiwen Xiao; Saijun Fan; Ming Cui
Journal:  Int J Mol Sci       Date:  2021-10-23       Impact factor: 5.923

7.  PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes.

Authors:  Shisuo Du; Lin Zhou; Gregory S Alexander; Kyewon Park; Lifeng Yang; Nadan Wang; Nicholas G Zaorsky; Xinliang Ma; Yajing Wang; Adam P Dicker; Bo Lu
Journal:  J Thorac Oncol       Date:  2017-12-13       Impact factor: 20.121

Review 8.  Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy.

Authors:  Yu-Jen Chen; Tung-Hu Tsai; Li-Ying Wang; Chen-Hsi Hsieh
Journal:  Technol Cancer Res Treat       Date:  2017-10-31

Review 9.  Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

Authors:  Jun Gong; Thang Q Le; Erminia Massarelli; Andrew E Hendifar; Richard Tuli
Journal:  J Immunother Cancer       Date:  2018-06-04       Impact factor: 13.751

10.  Is clinical target volume necessary?-a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique.

Authors:  Liqing Zou; Li Chu; Fan Xia; Lijun Zhou; Xi Yang; Jianjiao Ni; Junchao Chen; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2020-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.